AR and prostate carcinoma: To this end, we employed specific inhibitors to TBK1 (GSK8612; GSK) and JAK1/2 (Ruxolitnib; Ruxo) in prostate cancer cell lines and induced PARP7 via AHR (PC3, DU145) and AR (PC3-AR) (Supplementary Fig. S3).